Price movement over the last 24 hours
AdaptHealth Corp vs Autozone Inc — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while Autozone Inc trades at $3,072.08 (market cap $50.20B). The key difference: Autozone Inc is far larger — about 36.4× AdaptHealth Corp's market cap, and Autozone Inc is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | AZO | |
|---|---|---|
Market Cap | $1.38B | $50.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $13.38 | $4.35K |
52-Week Low | $8.68 | $2.94K |
Enterprise Value | $3.33B | $62.58B |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
AutoZone (AZO) trades at $3,074.86, down 2.67% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though profit margins have declined from 14.94% in 2022 to 13.19% in 2025. Recent Q1 2026 earnings beat expectations at $38.07 EPS versus $36.22 expected, while the board authorized an additional $1.5B stock repurchase in June 2026.
AZO presents a mixed outlook with 72.7% analyst buy ratings and $3,740 consensus target suggesting 21.6% upside, but faces technical headwinds and margin compression risks. Investment appeal hinges on international expansion execution and commercial segment growth offsetting domestic softness noted in recent earnings.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →